First real-world multicentre study of the use of inhaled aztreonam lysine for cystic fibrosis (CF)

Patients with CF are susceptible to recurrent chronic respiratory tract infections, which can exacerbate and increase the risk of death and morbidity. In this study we look at the real world effectiveness of the inhaled antibiotics aztreonam lysine (CAYSTON®) in routine clinical practice. Data from the study was presented at the European Cystic Fibrosis Society conference in 2014, and led to a successful re-submission to the SMC

SCott1
STUDY POPULATION

CF patients (n=117) who have commenced inhaled aztreonam lysine therapy across 9 CF centres

STUDY DESIGN

Retrospective chart notes review 1 year pre and post treatment with CAYSTON® using SVMPharma’s Treatment Evaluator tool

STUDY OUTCOME

Significantly improved lung function and weight. Reduced hospitalisation and exacerbation rates

followup3Chart notes
treament2Treatment data
doctor1Align with KOLs

SVMPharma’s innovative RWE solutions

Chart note is a rich and valuable source of RWE data

SVMPharma’s Treatment Evaluator tool helps collect this data

Real-world data helps inform treatment pathways and standard of care

SVMPharma’s RWE helps track comparator outcomes and routine clinical practices

Real-world data collection backed by KOLs

SVMPharma ensures real-world data is clinically relevant by engaging with KOLs

Reference: B. Plant et al. A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. Journal of Cystic Fibrosis 2017;16:695–701
Posted in Blogs.